Shares of Zydus Lifesciences saw a decline of more than two percent following the announcement of a notable profit drop. The net profit plunged thirty-six percent year-on-year for the first quarter, despite a nearly twenty-two percent increase in operational revenue. Expenses surged by over forty-one percent. However, the managing director remains optimistic about future prospects. Analysts at Nuvama have upgraded the stock to ‘Buy’, setting a higher price target.
SIP additions at a six-month high amid rising churn
In August, the number of new accounts for systematic investment plans (SIPs) soared to a six-month peak, marking significant activity. Nevertheless, the year-on-year growth showcased
September 21, 2026